DOI QR코드

DOI QR Code

Predictive Role of GSTs on the Prognosis of Breast Cancer Patients with Neoadjuvant Chemotherapy

  • Bai, Yun-Lu (Department of Ultrasound, the First Affiliated Hospital, Xinxiang Medical College) ;
  • Zhou, Bing (Department of General Surgery, the First Affiliated Hospital, Xinxiang Medical College) ;
  • Jing, Xiao-Yue (Department of General Surgery, the First Affiliated Hospital, Xinxiang Medical College) ;
  • Zhang, Bin (Department of General Surgery, the First Affiliated Hospital, Xinxiang Medical College) ;
  • Huo, Xiao-Qing (Department of Radiotherapy, the First Affiliated Hospital, Xinxiang Medical College) ;
  • Ma, Chao (Orthopedic Surgery, the First Affiliated Hospital, Xinxiang Medical College) ;
  • He, Jian-Miao (Department of General Surgery, the 309th Hospital of Chinese People's Liberation Army)
  • Published : 2012.10.31

Abstract

Objective: To evaluate the predictive value of GST gene polymorphisms with regard to prognosis of breast cancer patients receiving neoadjuvant chemotherapy. Methods: A total of 159 patients were included in our study between January 2005 and January 2007. All the patients were followed up until January 2012. Genotyping was based upon the duplex polymerase-chain-reaction with the PCR-CTPP method. Results: Patients with null GSTM1 and GSTP1 Val/Val genotypes had significantly had better response rates to chemotherapy when compared with non-null GSTM1 and GSTP1 Ile/Ile genotypes (OR=1.96 and OR=2.14, respectively). Patients with the GSTM1 null genotype had a longer average survival time and significantly lower risk of death than did those with non-null genotypes (HR=0.66). Similarly, those carrying the GSTP1 Val/Val genotype had 0.54-fold the risk of death of those with GSTP1 Ile/Ile (HR=0.54). Conclusion: A significant association was found between GSTM1 and GSTP1 gene polymorphisms and clinical outcomes in breast cancer cases.

Keywords

References

  1. Arun BK, Granville LA, Yin G, et al (2010). Glutathione-stransferase- pi expression in early breast cancer: association with outcome and response to chemotherapy. Cancer Investigation, 28, 554-9. https://doi.org/10.3109/07357900903286925
  2. Ates NA, Tamer L, Ateş C, et al (2005). Glutathione S-transferase M1, T1, P1 genotypes and risk for development of colorectal cancer. Biochem Genet, 43, 149-63. https://doi.org/10.1007/s10528-005-1508-z
  3. Bafaloukos D (2005). Neo-adjuvant therapy in breast cancer. Ann Oncol, 16, 174-81.
  4. Bosh TM, Meijerman I, Beijnen JH, et al (2006). Genetic polymorphisms of drug-metabolizing enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet, 45, 253-85. https://doi.org/10.2165/00003088-200645030-00003
  5. Franco RL, Schenka NG, Schenka AA, et al (2012). Glutathione S-transferase Pi expression in invasive breast cancer and its relation with the clinical outcome. J BUON, 17, 259-64.
  6. Funke S, Timofeeva M, Risch A, et al (2010). Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy. Pharmacogenomics, 11, 33-41. https://doi.org/10.2217/pgs.09.132
  7. International Agency for Research on Cancer (2008). Globocan 2008: Stomach Cancer incidence, Mortality and Prevalence Worldwide in 2008. IARC. http://globocan.iarc.fr/factsheets/cancers/liver.asp.
  8. Lourenco GJ, Lorand-Metze I, Delamain MT, et al (2010). Polymorphisms of glutathione S-transferase mu 1, theta 1, and pi 1 genes and prognosis in Hodgkin lymphoma. Leuk Lymphoma, 51, 2215-21. https://doi.org/10.3109/10428194.2010.527402
  9. Mishra A, Chandra R, Mehrotra PK, et al (2011). Glutathione S-transferase M1 and T1 polymorphism and response to neoadjuvant chemotherapy (CAF) in breast cancer patients. Surg Today, 41, 471-6. https://doi.org/10.1007/s00595-009-4310-4
  10. Mossallam GI, Abdel Hamid TM, Samra MA (2006). Glutathione S-transferase GSTM1 and GSTT1 polymorphisms in adult acute myeloid leukemia; its impact on toxicity and response to chemotherapy. J Egypt Natl Canc Inst, 18, 264-73.
  11. Nagle CM, Chenevix-Trench G, Spurdle AB, et al (2007). The role of glutathione-S-transferase polymorphisms in ovarian cancer survival. Eur J Cancer, 43, 283-90. https://doi.org/10.1016/j.ejca.2006.09.011
  12. Oliveira AL, Rodrigues FF, Santos RE, et al (2010). GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer. Genet Mol Res, 9, 1045-53. https://doi.org/10.4238/vol9-2gmr726
  13. Ott K, Lordick F, Becker K, et al (2008). Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients. Int J Colorectal Dis, 23, 773-82. https://doi.org/10.1007/s00384-008-0490-4
  14. Satta T, Isobe K, Yamauchi M, et al (1992). Expression of MDR1 and glutathione S transferase-pi genes and chemosensitivities in human gastrointestinal cancer. Cancer, 69, 941-6. https://doi.org/10.1002/1097-0142(19920215)69:4<941::AID-CNCR2820690418>3.0.CO;2-H
  15. Wang W, Xia CQ, Liu N, et al (2008). Mechanistic study of potentiation of chemotherapy by a haloenol lactone derivative in vitro. Cancer Chemother Pharmacol, 62, 117-22. https://doi.org/10.1007/s00280-007-0581-x
  16. Wang L, Jiang Z, Sui M, et al (2009). The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study. BMC Cancer, 9, 226. https://doi.org/10.1186/1471-2407-9-226
  17. Whelan RD, Waring CJ, Wolf CR, et al (1992). Overexpression of P-glycoprotein and glutathione S-transferase pi in MCF-7 cells selected for vincristine resistance in vitro. Int J Cancer, 52, 241-6. https://doi.org/10.1002/ijc.2910520215
  18. Zheng J, Wurz GT, Cadman TB, et al (1997). Haloenol lactone: a new synergist of chemotherapy in vitro. Biochem Biophys Res Commun, 241, 13-7. https://doi.org/10.1006/bbrc.1997.7762

Cited by

  1. Is Axillary Dissection Necessary for Breast Cancer in Old Women? A Meta-analysis of Randomized Clinical Trials vol.14, pp.2, 2013, https://doi.org/10.7314/APJCP.2013.14.2.947
  2. Genetic variability of glutathione S-transferases influences treatment outcome of breast cancer vol.36, pp.8, 2015, https://doi.org/10.1007/s13277-015-3266-9
  3. GSTT1 and GSTM1 polymorphisms predict treatment outcome for breast cancer: a systematic review and meta-analysis vol.37, pp.1, 2016, https://doi.org/10.1007/s13277-015-4401-3
  4. GSTP1, GSTM1, and GSTT1 polymorphisms as predictors of response to chemotherapy in patients with breast cancer: a meta-analysis vol.78, pp.6, 2016, https://doi.org/10.1007/s00280-016-3173-9
  5. Interaction between glutathione S-transferase M1-null/present polymorphism and adjuvant chemotherapy influences the survival of breast cancer vol.7, pp.9, 2018, https://doi.org/10.1002/cam4.1567